[ad_1]
Trials from coronary vaccine giant AstraZeneca were suspended after a test subject in the UK contracted a potentially unexplained disease.
The phase 3 trial of the vaccine, which is being developed by AstraZeneca and the University of Oxford in various parts of the US, was discontinued after a review of the vaccine trials, writes the news website Stat .
The AstraZeneca coronary vaccine is in the final stages of testing. The vaccine is being tested in Phase 3 in the United States and in Phases 2 and 3 in the United Kingdom, Brazil, and South Africa.
The company did not provide further information on the type of symptoms the test person had, but an AstraZeneca spokesperson described the breakdown as a “standard routine that should be followed when a potentially unexplained illness is detected in a test.”
AstraZeneca is considered one of the main candidates to develop a covid-19 vaccine, and the European Commission has signed an agreement with the pharmaceutical company. The cooperation will also apply to Norway, the government declared in mid-August.
Temporary suspension in important medical studies is not uncommon, and examination of serious or unexplained effects is a necessary part of the evidence. AstraZeneca notes that the problem may be a coincidence, as the disease can occur in people who participate in such a study.
– We are working to accelerate the review to reduce the possible impact on the trial period, it is stated in the statement from the pharmaceutical company.
(© NTB)
[ad_2]
